RecruitingLung CancerHepatocellular CarcinomaSolid Tumor
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Eligible age
18–80 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
You may qualify if…
- ✓ Solid advanced malignant tumors
- ✓ Age between18 and 80 years
- ✓ Life expectancy is greater than three months
You may not qualify if…
- ✕ Benign tumor
- ✕ Life expectancy is less than three months
- ✕ Serious medical comorbidity
- ✕ Others
Source: ClinicalTrials.gov · NCT04952272 · last updated 2024-06-26